BamSEC and AlphaSense Join Forces
Learn More

Vanda Pharmaceuticals Inc. – Material Contracts

NASDAQ: VNDA    
Share price (11/20/26): $3.44    
Market cap (11/20/26): $208 million

Material Contracts Filter

EX-10.3
from 10-Q 9 pages Vanda Pharmaceuticals Inc. Employment Agreement This Employment Agreement (This “Agreement”) Is Entered Into as of August 20, 2026 by and Between Scott Howell (The “Executive”) and Vanda Pharmaceuticals Inc., a Delaware Corporation (The “Company”). 1. Duties and Scope of Employment
12/34/56
EX-10.2
from 10-Q 9 pages Vanda Pharmaceuticals Inc. Employment Agreement This Employment Agreement (This “Agreement”) Is Entered Into as of August 20, 2026 by and Between Christos Polymeropoulos (The “Executive”) and Vanda Pharmaceuticals Inc., a Delaware Corporation (The “Company”). 1. Duties and Scope of Employment
12/34/56
EX-10.1
from 10-Q 9 pages Vanda Pharmaceuticals Inc. Employment Agreement This Employment Agreement (This “Agreement”) Is Entered Into as of August 20, 2026 by and Between Daniel McGuire (The “Executive”) and Vanda Pharmaceuticals Inc., a Delaware Corporation (The “Company”). 1. Duties and Scope of Employment
12/34/56
EX-10.1
from 10-Q 11 pages Amendment No. 8 to Lease
12/34/56
EX-10.1
from S-8 22 pages Vanda Pharmaceuticals Inc. 2016 Equity Incentive Plan
12/34/56
EX-10.1
from 8-K 5 pages Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan: Notice of Performance Restricted Stock Unit Award
12/34/56
EX-10.1
from 10-Q 7 pages Amendment No. 7 to Lease
12/34/56
EX-10.1
from S-8 21 pages Vanda Pharmaceuticals Inc. 2016 Equity Incentive Plan
12/34/56
EX-10.1
from 10-Q 5 pages Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan: Notice of Restricted Stock Unit Award
12/34/56
EX-10.1
from S-8 20 pages Vanda Pharmaceuticals Inc. 2016 Equity Incentive Plan
12/34/56
EX-10.47
from 10-K 54 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both (I) Not Material and (II) the Type That the Registrant Normally Treats as Private and Confidential. Such Excluded Information Has Been Marked “[***]”. Asset Purchase Agreement by and Between Actelion Pharmaceuticals Ltd. and Vanda Pharmaceuticals Inc. Dated as of December 7, 2023
12/34/56
EX-10.8
from 10-Q 9 pages Uk Sub-Plan to the Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan Notice of Stock Option Grant
12/34/56
EX-10.7
from 10-Q 5 pages Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan Notice of Stock Option Grant
12/34/56
EX-10.6
from 10-Q 6 pages Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan Notice of Stock Option Grant
12/34/56
EX-10.5
from 10-Q 5 pages Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan Notice of Stock Option Grant
12/34/56
EX-10.4
from 10-Q 7 pages Uk Sub-Plan to the Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan: Notice of Restricted Stock Unit Award
12/34/56
EX-10.3
from 10-Q 3 pages Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan: Notice of Restricted Stock Unit Award
12/34/56
EX-10.2
from 10-Q 5 pages Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan: Notice of Restricted Stock Unit Award
12/34/56
EX-10.1
from 10-Q 5 pages Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan: Notice of Restricted Stock Unit Award
12/34/56
EX-10.2
from 10-Q 5 pages Vanda Pharmaceuticals Inc. Amended and Restated 2016 Equity Incentive Plan: Notice of Restricted Stock Unit Award
12/34/56